NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

GSK (NYSE: GSK - Get Free Report) and Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) are

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth qu

U.S. futures rise, but Xenon plunges 27.6% after pausing psychiatry trial enrollment over neuropsych

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company commit

Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) and Bristol Myers Squibb (NYSE: BMY - Get

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

RADNOR, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor

EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve

Investigation Alert: EyePoint, Inc. (EYPT) Investors are Encouraged to Contact Kessler Topaz Meltzer

RADNOR, Pa., Sept. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nati

RADNOR, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EY

Wall Street analysts changed outlook on top companies. Check out complete rating changes, including

TD Cowen analyst Tara Bancroft downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold and lowers the

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.

EYPT releases topline results from Phase 3 LUGANO trial for wet AMD treatment. While primary endpoin

Citigroup analyst Yigal Nochomovitz maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the pr

RBC Capital analyst Lisa Walter downgrades EyePoint (NASDAQ:EYPT) from Outperform to Sector Perfo

Chardan Capital analyst Andreas Argyrides downgrades EyePoint (NASDAQ:EYPT) from Buy to Neutral a

Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.51% to 53,

Ocular Therapeutix stock jumps 6% as rival EyePoint misses Phase 3 primary endpoint for wet AMD trea

Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's reg

Jefferies analyst Kambiz Yazdi maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers the price t

US stocks mixed, S&P 500 drops 0.2%. Dow down 0.34%, NASDAQ up 0.04%. Industrials up 0.2%, consu

EyePoint reported Phase 3 LUGANO trial results for DURAVYU, highlighting reduced treatment burden de

US stocks mixed, Dow falls 150 points. Dow down 0.31%, NASDAQ up 0.03%, S&P 500 down 0.12%. Tech

Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-mar

EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative thera

– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc a

Analysts changed outlook on top names: JP Morgan cut price target for Insulet, HC Wainwright slashed

Cantor Fitzgerald analyst Steve Seedhouse maintains EyePoint (NASDAQ:EYPT) with a Overweight and

HC Wainwright & Co. analyst Yi Chen maintains EyePoint (NASDAQ:EYPT) with a Buy and lowers th

EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(1.09) per share which missed t

Wall Street analysts change outlook on top names. Check out analyst ratings page for upgrades, downg

Stifel analyst Annabel Samimy initiates coverage on EyePoint (NASDAQ:EYPT) with a Buy rating and

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Cantor Fitzgerald analyst Steve Seedhouse assumes EyePoint (NASDAQ:EYPT) with a Overweight rating

Chardan Capital analyst Andreas Argyrides maintains EyePoint (NASDAQ:EYPT) with a Buy and raises

RBC Capital analyst Lisa Walter maintains EyePoint (NASDAQ:EYPT) with a Outperform and lowers the

On March 20, 2026, EyePoint, Inc. (the "Company") filed a complaint against Ocular Therapeut